These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 28317807)
1. Tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione derivatives as novel antibacterial compounds against Koseki Y; Kanetaka H; Tsunosaki J; Munier-Lehmann H; Aoki S Int J Mycobacteriol; 2017; 6(1):61-69. PubMed ID: 28317807 [TBL] [Abstract][Full Text] [Related]
2. Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library. Koseki Y; Kinjo T; Kobayashi M; Aoki S Eur J Med Chem; 2013 Feb; 60():333-9. PubMed ID: 23314046 [TBL] [Abstract][Full Text] [Related]
3. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795 [TBL] [Abstract][Full Text] [Related]
4. Identification of compounds with potential antibacterial activity against Mycobacterium through structure-based drug screening. Kinjo T; Koseki Y; Kobayashi M; Yamada A; Morita K; Yamaguchi K; Tsurusawa R; Gulten G; Komatsu H; Sakamoto H; Sacchettini JC; Kitamura M; Aoki S J Chem Inf Model; 2013 May; 53(5):1200-12. PubMed ID: 23600706 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening. Taira J; Morita K; Kawashima S; Umei T; Baba H; Maruoka T; Komatsu H; Sakamoto H; Sacchettini JC; Aoki S J Antibiot (Tokyo); 2017 Nov; 70(11):1057-1064. PubMed ID: 28951604 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Altaf M; Miller CH; Bellows DS; O'Toole R Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of mycobacterial growth by plumbagin derivatives. Mathew R; Kruthiventi AK; Prasad JV; Kumar SP; Srinu G; Chatterji D Chem Biol Drug Des; 2010 Jul; 76(1):34-42. PubMed ID: 20456370 [TBL] [Abstract][Full Text] [Related]
10. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach. Kanetaka H; Koseki Y; Taira J; Umei T; Komatsu H; Sakamoto H; Gulten G; Sacchettini JC; Kitamura M; Aoki S Eur J Med Chem; 2015 Apr; 94():378-85. PubMed ID: 25778993 [TBL] [Abstract][Full Text] [Related]
11. Elaboration of a proprietary thymidylate kinase inhibitor motif towards anti-tuberculosis agents. Song L; Risseeuw MDP; Froeyen M; Karalic I; Goeman J; Cappoen D; Van der Eycken J; Cos P; Munier-Lehmann H; Van Calenbergh S Bioorg Med Chem; 2016 Nov; 24(21):5172-5182. PubMed ID: 27614917 [TBL] [Abstract][Full Text] [Related]
12. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494 [TBL] [Abstract][Full Text] [Related]
13. Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors. Song L; Merceron R; Hulpia F; Lucía A; Gracia B; Jian Y; Risseeuw MDP; Verstraelen T; Cos P; Aínsa JA; Boshoff HI; Munier-Lehmann H; Savvides SN; Van Calenbergh S Eur J Med Chem; 2021 Dec; 225():113784. PubMed ID: 34450493 [TBL] [Abstract][Full Text] [Related]
14. Identification and optimization of a new series of anti-tubercular quinazolinones. Couturier C; Lair C; Pellet A; Upton A; Kaneko T; Perron C; Cogo E; Menegotto J; Bauer A; Scheiper B; Lagrange S; Bacqué E Bioorg Med Chem Lett; 2016 Nov; 26(21):5290-5299. PubMed ID: 27671498 [TBL] [Abstract][Full Text] [Related]
15. Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors. Song L; Merceron R; Gracia B; Quintana AL; Risseeuw MDP; Hulpia F; Cos P; Aínsa JA; Munier-Lehmann H; Savvides SN; Van Calenbergh S J Med Chem; 2018 Apr; 61(7):2753-2775. PubMed ID: 29510037 [TBL] [Abstract][Full Text] [Related]
16. 5-Arylaminouracil Derivatives: New Inhibitors of Mycobacterium tuberculosis. Matyugina E; Novikov M; Babkov D; Ozerov A; Chernousova L; Andreevskaya S; Smirnova T; Karpenko I; Chizhov A; Murthu P; Lutz S; Kochetkov S; Seley-Radtke KL; Khandazhinskaya AL Chem Biol Drug Des; 2015 Dec; 86(6):1387-96. PubMed ID: 26061192 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and inhibitory activity of thymidine analogues targeting Mycobacterium tuberculosis thymidine monophosphate kinase. Van Poecke S; Munier-Lehmann H; Helynck O; Froeyen M; Van Calenbergh S Bioorg Med Chem; 2011 Dec; 19(24):7603-11. PubMed ID: 22061826 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and In vitro antituberculosis activity of 2(5H)-Furanone derivatives. Ngwane AH; Panayides JL; Chouteau F; Macingwana L; Viljoen A; Baker B; Madikane E; de Kock C; Wiesner L; Chibale K; Parkinson CJ; Mmutlane EM; van Helden P; Wiid I IUBMB Life; 2016 Aug; 68(8):612-20. PubMed ID: 27346745 [TBL] [Abstract][Full Text] [Related]